Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
Public ClinicalTrials.gov record NCT00577135. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Heart failure is a disorder in which the heart does not pump blood adequately. This can lead to several serious problems, including reduced blood flow throughout the body, congestion of blood in the veins and lungs, and fluid accumulation in various organs and limbs. Diuretics are often used to address the problem of fluid accumulation, but the optimal dose and the amount of time over which to administer each dose are unclear. This study will compare high and low doses of diuretics administered over longer and shorter periods of time to determine the safest and most effective combination.
Study identification
- NCT ID
- NCT00577135
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 308 participants
Conditions and interventions
Conditions
Interventions
- Furosemide-Q12 hour bolus Drug
- Furosemide-Continuous Infusion Drug
- Furosemide-Low Intensification Drug
- Furosemide-High Intensification Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2008
- Primary completion
- Dec 31, 2009
- Completion
- Jan 31, 2010
- Last update posted
- Mar 5, 2018
2008 – 2010
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Morehouse School of Medicine | Atlanta | Georgia | 30310 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Minnesota Heart Failure Network | Minneapolis | Minnesota | 55415 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| University of Utah Health Sciences Center | Murray | Utah | 84107 | — |
| University of Vermont - Fletcher Allen Health Care | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00577135, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2018 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00577135 live on ClinicalTrials.gov.